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Stephen J. Nicholls, MBBS, PHD,yz Alex Brown, MBBS, PHDyxSEE PAGE 851D espite the established beneﬁts of random-ized controlled trials in the primary andsecondary prevention settings, atheroscle-
rotic cardiovascular disease continues to present a
major public health challenge throughout the world.
Beyond the critical, often overlooked importance of
lifestyle measures, new efforts to improve disease
prevention will require more effective approaches to
tailor risk assessment and subsequently to modify
that risk. The successful targeting of low-density
lipoprotein cholesterol (LDL-C) represents a model
on which to base these future developments. The
ﬁndings that LDL-C levels are directly associated
with cardiovascular risk and that lowering its levels
results in fewer clinical events underscore the impor-
tance of LDL-C in strategies designed to prevent car-
diovascular disease (1).
However, the ﬁndings that many persons judged to
be not at high risk by standard risk prediction models
experience clinical events (2) and that adverse
cardiovascular outcomes continue to be observed in
patients who undergo intensive modiﬁcation of
traditional risk factors (3) suggest an urgent need to
develop additional approaches to risk stratiﬁcation.
Although ongoing studies are evaluating LDL-C–
lowering strategies in addition to statins, attention
also has turned to a range of other lipid factors
implicated in atherosclerotic disease. High-density
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tion from heart disease, in terms of both association
with risk (4) and the lack of efﬁcacy of HDL-C–raising
therapies (5,6). Increasing evidence implicates an
independent role for measurements of triglycerides
(7), as well as remnant lipoprotein particles (8), in
risk prediction. However, the demonstration that
lowering the levels of these substances translates to
clinical beneﬁt remains to be established.
In parallel, lipoprotein (a), abbreviated Lp(a), con-
tinues to receive considerable attention with regard
to its potential role in promoting atherosclerosis and
its role in risk reduction strategies. Lp(a) has unique
structural properties that combine stimulatory effects
on atherogenic and thrombotic pathways that un-
derlie the pathogenesis of acute ischemic events (9).In this issue of the Journal, Willeit et al. (10) report
ﬁndings of their investigation on the capability of
Lp(a) levels to discriminate cardiovascular risk over a
15-year period in the Bruneck Study. In this
community-based study of 826 men and women who
were 45 to 84 years old, a direct relationship was
observed between Lp(a) levels and the subsequent
incidence of major adverse cardiovascular events.
This ﬁnding supports a growing body of evidence
linking Lp(a) levels and cardiovascular risk. Most
importantly, however, the current analysis provides
compelling evidence to support a potential role of
Lp(a) in reclassiﬁcation of patients previously deter-
mined to be at intermediate cardiovascular risk on the
basis of traditional algorithms. In fact, nearly 2 in 5 of
such patients underwent restratiﬁcation to either
lower or higher cardiovascular risk settings.
Although these observations are of potential in-
terest in expanding the clinical use of Lp(a), certain
issues remain unresolved. Do such ﬁndings inﬂuence
the integration of Lp(a) testing into risk prediction
algorithms? In general, the use of this testing is not
widespread; it tends to be conﬁned to subsets of
patients, including those with premature coronary
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862disease in the absence of any major cardiovascular
risk factor. Whether systematic screening of Lp(a) will
be of clinical beneﬁt will ultimately require validation
that it changes practice and clinical outcomes in a
cost-effective manner. Such studies have not been
performed. Similarly, the relative utility of serial
evaluation of Lp(a) is untested. Increasing evidence
has highlighted the potential differences between
Lp(a) isoforms with regard to their relationship with
cardiovascular risk (9). Of particular interest, no such
association was demonstrated in the current analysis
beyond the predictive capability of Lp(a) levels.
Ultimately, we need to ask how such measurements
will change clinical practice. In an ever-changing
world of lipid guidelines, some countries will use
Lp(a) to identify higher-risk patients, whereas other
countries, wanting to adhere more closely to evidence
from randomized clinical trials, will ﬁnd an absence
of data. Most physicians who routinely measure
Lp(a) levels will use such results for triage of patients
to more intensive use of established preventive
therapies. The ﬁnding that Lp(a) levels tend to be
less predictive of cardiovascular outcomes in patients
with very low LDL-C levels supports, but does
not validate, the use of more intensive statin therapy
(11). The concept of developing agents that speciﬁcallylower Lp(a) levels and in turn reduce event rates
is attractive. Disappointingly, estrogen and nico-
tinic acid both lower Lp(a), among their other
actions, yet they did not reduce cardiovascular
event rates in clinical trials. Experimental therapies
with, for example, cholesteryl ester transfer pro-
tein (CETP) and proprotein convertase subtilisin
kexin type 9 (PCSK9) inhibitors lower Lp(a), but
any potential clinical beneﬁt is likely derived
from other lipid effects. Whether a more selective
Lp(a)-lowering strategy will prove protective remains
to be tested.
This body of evidence supports a potential role
for Lp(a) as both a risk marker and a target for
therapeutic lowering. Whether Lp(a) will identify
the patient with modiﬁable cardiovascular risk is
unknown. The ﬁeld is in great need of clinical
trials to determine the optimal use of Lp(a). As a
result, the journey of Lp(a) toward routine use
continues.
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